The purpose of the present trial is to obtain information on the absorption, distribution, metabolism, excretion and pharmacokinetics (PK) of 14C-SEP-380135 and its metabolites following a single oral dose.
Body mass index (BMI) between 18.0 and 32.0 kilograms per square meter (kg/m²).
Medical history
Physical examination
Neurological examination
Have taken an investigational drug within 30 days or 5 half-lives, if known, (whichever is longer) prior to screening.
Have had prior exposure to SEP-380135.
Are currently participating in another clinical trial.
Attempted suicide within 12 months prior to screening.